“One of the leading CAR T-cells immunotherapy company, Cellectis dosed the first blood cancer patient with the allogeneic, “off-the-shelf” CAR-T therapy, UCART123 at Weill Cornell Medicine and NewYork-Presbyterian Hospital…”
Scientists Get Closer to First CAR T-Cells Based Immunotherapy for Humans
Cellectis’ off-the-shelf CAR-T Cancer Therapy has Entered the Clinic
Cellectis’ Press Release…
A journalist from Bloomberg News is working on a story similar to the one below:
For experimental cancer therapy, a struggle to ensure supply keeps up with demand | Science | AAAS
“The sky-high cost of producing CAR T cells, and limitations on the availability and regulatory qualification of reagents can be barriers to making CAR T cell therapy accessible…”
Biotechin.Asia- Driving CAR T-Cell Therapy From Bench to Bedside
CAR-T Value Calculation In The Firing Line | Seeking Alpha
Work continues on applying CAR-T to solid tumors:
Unleashing CAR-T Therapies on Solid Tumors: Are We There Yet? | BIOtechNow
A history of all reported deaths (clinically described as a “Grade 5 Adverse Event”) thus far from CAR-T:
EP Vantage – Spotlight – Putting a number on CAR-T deaths
Neurotoxicity needs separate treatment from CRS in CAR T-cell therapy | (Free registration required)
CAR-T coverage in PC Magazine(!)
How Scientists Are Hacking Cancer | News & Opinion | PCMag.com
CAR-T and Follicular Non-Hodgkin's Lymphoma 
I wonder whether patients receiving off-the-shelf UCART123 will experience graft-vs-host-disease (GVHD) which is common in transplants?
LikeLike
I was wondering about that as well. Perhaps it’s less of an issue with a donor’s T cells than with stem cells? I haven’t yet had any issues with blood or IgIV infusions.
LikeLike
Yes, but your CAR-T was made from your own T-cells so GVHD was a non-issue. It may be an issue using T-cells from another person, right???
LikeLike
CAR-T cells are made for each patient from their own T cells. No GVHD! It’s a great relief.
LikeLike